Cargando…

Tolerability and efficacy of paliperidone ER compared to olanzapine in the treatment of schizophrenia: A randomized, double–blind, multicentric trial

BACKGROUND: Paliperidone is an active metabolite of risperidone and actss through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. AIM: The present randomized, double-blind, multicentric trial was designed to determine the safety and efficacy of paliper...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, Sandip, Joshi, Dipti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425242/ https://www.ncbi.nlm.nih.gov/pubmed/22969177 http://dx.doi.org/10.4103/0972-6748.98411

Ejemplares similares

A Flexible-Dose Study of Paliperidone ER in Patients With Nonacute Schizophrenia Previously Treated Unsuccessfully With Oral Olanzapine
por: KOTLER, MOSHE, et al.
Publicado: (2016)

Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: a flexible-dose approach
por: Mauri, Mauro, et al.
Publicado: (2015)

Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia
por: Takahashi, Nagahide, et al.
Publicado: (2013)

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
por: Turkoz, Ibrahim, et al.
Publicado: (2011)

PM380. Treatment successful rate and efficacy of Paliperidone ER in patients with acute schizophrenia
por: Chen, Yi-hsing
Publicado: (2016)

Manic Symptoms during a Switch from Paliperidone ER to Paliperidone Palmitate in a Patient with Schizophrenia
por: Demirci, Kadir, et al.
Publicado: (2015)

Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability
por: Bellino, Silvio, et al.
Publicado: (2011)

Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
por: Savitz, Adam J., et al.
Publicado: (2016)

A Randomized Controlled Trial to Compare the Efficacy, Safety and Tolerability of Asenapine versus Olanzapine in Management of Schizophrenia
por: Maitra, Arpita, et al.
Publicado: (2020)

Influencing Factors and Predictors of Early Response in Schizophrenia Patients Receiving the Paliperidone Extended-Release Tablets (Paliperidone ER)
por: Jung, Seung-Ho, et al.
Publicado: (2013)

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder
por: Deberdt, Walter, et al.
Publicado: (2008)

Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER
por: Birnbaum, Michael, et al.
Publicado: (2008)

Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice
por: Peuskens, Joseph, et al.
Publicado: (2014)

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
por: Gattaz, Wagner F, et al.
Publicado: (2020)

Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial
por: Bossie, Cynthia A, et al.
Publicado: (2011)

Long-term efficacy and safety of paliperidone 6-month formulation: An open-label extension of a double-blind study in adult patients with schizophrenia
por: Najarian, D., et al.
Publicado: (2023)

A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia
por: Najarian, Dean, et al.
Publicado: (2021)

Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study
por: Si, Tian Mei, et al.
Publicado: (2019)

Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia
por: Suresh Kumar, P. N., et al.
Publicado: (2016)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
por: Zhang, Hongyan, et al.
Publicado: (2016)

Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia
por: Lu, Mong-Liang, et al.
Publicado: (2016)

A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation
por: Katagiri, Hideaki, et al.
Publicado: (2013)

Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia
por: Spina, Edoardo, et al.
Publicado: (2011)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
por: Zhang, Fan, et al.
Publicado: (2015)

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
por: Savitz, Adam J, et al.
Publicado: (2017)

Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study
por: Giron‐Hernandez, Cesar, et al.
Publicado: (2023)

Paliperidone ER: a review of the clinical trial data
por: Janicak, Philip G, et al.
Publicado: (2007)

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2011)

Erratum: A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation
por: Katagiri, Hideaki, et al.
Publicado: (2014)

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies
por: Gopal, Srihari, et al.
Publicado: (2017)

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
por: Alphs, Larry, et al.
Publicado: (2011)

PM419. Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study
por: Savitz, A, et al.
Publicado: (2016)

Paliperidone: the evidence of its therapeutic value in schizophrenia
por: Kantrowitz, Joshua, et al.
Publicado: (2007)

Once-monthly paliperidone injection for the treatment of schizophrenia
por: Bishara, Delia
Publicado: (2010)

PM394. The outcome of paliperidone palmitate in schizophrenia
por: Ju, Po-Chung
Publicado: (2016)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
por: Sliwa, Jennifer Kern, et al.
Publicado: (2012)

Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophrenia
por: Helldin, Lars, et al.
Publicado: (2015)

A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia
por: Shoja Shafti, Saeed, et al.
Publicado: (2014)

Paliperidone Compared with Haloperidol on the Theory of Mind Tasks in Schizophrenia: A Pilot Trial
por: Zhong, Jie, et al.
Publicado: (2021)

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies
por: Savitz, Adam J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tpf9mdfc7bk4uesv7q4va6psac